Concepedia

Publication | Closed Access

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

441

Citations

18

References

2003

Year

Andrew M. Scott, G. Wiseman, Sydney Welt, Alex A. Adjei, Fook-Thean Lee, Wendie Hopkins, C R Divgi, Lorelei H Hanson, Paul Mitchell, Denise N. Gansen,
PubMed

Abstract

Repeat infusions of the humanized anti-FAP antibody sibrotuzumab can be administered safely to patients with advanced FAP-positive cancer.

References

YearCitations

Page 1